Preventing HER2 degradation improves efficacy of trastuzumab deruxtecan
Crossref DOI link: https://doi.org/10.1038/s43018-025-01106-x
Published Online: 2026-01-29
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Lewis, Gail D. https://orcid.org/0000-0001-7051-016X
Text and Data Mining valid from 2026-01-29
Version of Record valid from 2026-01-29
Article History
First Online: 29 January 2026
Competing interests
: The author is a full-time employee of Genentech and a shareholder of the Roche Group.